Brief: Cogent Biosciences Announces Positive Lead-In Data From Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib In Combination With Sunitinib

Cogent Biosciences

03/06/2023 19:27

June 3 (Reuters) - Cogent Biosciences Inc  COGT.O :
    * COGENT BIOSCIENCES ANNOUNCES POSITIVE LEAD-IN DATA FROM
ONGOING
PHASE 3 PEAK TRIAL EVALUATING BEZUCLASTINIB IN COMBINATION WITH
SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
(GIST)
    * COGENT -  DATA PRESENTED DEMONSTRATE 55% DISEASE CONTROL
RATE 
IN HEAVILY PRE-TREATED GIST PATIENTS FOR BEZUCLASTINIB IN
COMBINATION WITH SUNITINIB
    * DATA PRESENTED SHOW 17% OVERALL RESPONSE RATE (ORR) IN
EFFICACY
EVALUABLE 2(ND)-LINE GIST PATIENTS
    * COGENT BIOSCIENCES - COMBINATION OF BEZUCLASTINIB AND
SUNITINIB
IS WELL-TOLERATED AND CONSISTENT WITH PUBLISHED SUNITINIB
MONOTHERAPY SAFETY PROFILE
    * COGENT - MAJORITY OF TREATMENT-EMERGENT ADVERSE EVENTS 
WERE
LOW-GRADE AND REVERSIBLE FOR BEZUCLASTINIB IN COMBINATION WITH
SUNITINIB

Source text for Eikon:  ID:nGNX9pcvXK 
Further company coverage:  COGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))